Abalone Bio GTM brain

Abalone Bio develops activating antibody therapeutics for difficult GPCR targets and partners with pharmaceutical companies on discovery and assets.

category

GPCR antibody discovery and therapeutics

market profile

  • text: Biopharma teams seek selective, long-acting agonists for GPCRs, but binding a receptor is not evidence of activation.
  • text: Its programs remain preclinical; Pfizer has announced a target-specific discovery collaboration.
  • text: The company combines its own therapeutic pipeline with external discovery and co-development partnerships.

personas

  • title: VP of antibody discovery
    pains:
    • Binding screens do not establish the functional activity needed for a receptor agonist.
    • Rare activating antibodies against membrane receptors are difficult to find.
  • title: Head of metabolic disease research
    pains:
    • Developing selective, long-acting therapies while managing tolerability risks
    • Moving a candidate from receptor activity to convincing in vivo evidence
  • title: Pharma business development director
    pains:
    • Finding differentiated external programs and negotiating rights to promising assets
    • Evaluating platform feasibility, reproducibility and target-specific risk before investment

icp

  • text: Pharmaceutical companies with established GPCR research and capacity to fund external antibody discovery collaborations, exemplified by Pfizer.
  • text: Biotech or pharma teams with metabolic disease, fibrosis or pain portfolios that can license or co-develop preclinical assets; no minimum company size is established.

message pillars

  • text: Screen for functional activation rather than relying only on binding.
  • text: Measure antibody function at very large library scale.
  • text: Combine selection data with machine learning to find and design agonists.
  • text: Offer partners preclinical programs in fibrosis and pain.

objections

  • objection: Does a functional hit translate into a viable medicine?
    response: Review target-specific preclinical data and agree on independent validation and development milestones; animal evidence is not clinical proof.
  • objection: Will this approach work on our receptor?
    response: Discuss target biology, assay feasibility and agreed technical milestones before a broad partnership.
  • objection: How are ownership and economics handled?
    response: Scope the target, rights and development responsibilities in a bilateral partnership negotiation.

competitors

  • name: AbCellera
    why: Antibody discovery and development company with a GPCR or ion channel program competing for biopharma partnerships.
  • name: DJS Antibodies
    why: Antibody discovery company focused on difficult membrane protein and GPCR targets.
  • name: Maxion Therapeutics
    why: Biotech working on antibody-derived molecules for challenging membrane protein targets.

influencers

  • name: Richard Yu
    url: https://bioneex.com/stories/developing-functional-antibodies-that-modulate-target-activity
    why: Co-founder and CEO discussing the scientific approach and partnership strategy.

keywords

  • GPCR antibody agonist discovery
  • functional antibody screening
  • GPCR drug discovery partnership
  • antibody agonist licensing
  • obesity antibody therapeutics
  • antibody activity screening

voice

  • Scientifically specific
  • Patient outcome focused
  • Confident about challenging targets

signals

  • text: A pharma company announces a new GPCR discovery program or seeks external antibody discovery capabilities.
  • text: A drug developer is building a metabolic, fibrosis or pain portfolio and seeking preclinical assets.

pricing

model: unknown

motion

sales_led

channels

  • pharma partnerships
  • scientific publications
  • LinkedIn

confidence

medium

Founders

  • name: Richard Yu
    title: Founder
    role: Founder
    bio: Rich has been in or around biotech startups since 2008, when co-founded GPB, an algae biofuel startup. He was also Scientific and Operations Director at MBC Biolabs, the leading biotech incubator in SF, and Principal at Mission Bay Capital, a life science VC fund. Prior, he was an investigator at The Molecular Sciences Institute studying how cells process information. PhD (2000) Molecular Biophysics and Biochemistry, Yale BA (1993) Biophysics and Computer Science (AI and Graphics), UC Berkeley
  • name: Gustavo Pesce
    title: Founder
    role: Founder

Back to YC companies